Oct 14 2024 |
et al., Scientia Pharmaceutica, doi:10.3390/scipharm92040056 | Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial |
| RCT with 29 mild COVID-19 outpatients in Switzerland, showing no significant difference with methylene blue treatment. There was a trend towards faster viral clearance. There were no serious adverse events. The trial was discontinued earl.. | ||
May 29 2023 |
et al., Pharmaceuticals, doi:10.3390/ph16060799 | Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients |
| RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with mebendazole. Authors note that mebendazole, like ivermectin, has been shown to have antiviral activity against multiple viruses. | ||
Dec 10 2022 |
et al., Advances in Virology, doi:10.1155/2022/3014686 | The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study |
| Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outp.. | ||
Dec 10 2022 |
et al., Advances in Virology, doi:10.1155/2022/3014686 | The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study |
| Retrospective 157 inpatients and 185 outpatients, showing improved recovery with mebendazole. For outpatients, the treatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable. The outp.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.